ATE215949T1 - Hydroisochinolinderivate - Google Patents
HydroisochinolinderivateInfo
- Publication number
- ATE215949T1 ATE215949T1 AT94924764T AT94924764T ATE215949T1 AT E215949 T1 ATE215949 T1 AT E215949T1 AT 94924764 T AT94924764 T AT 94924764T AT 94924764 T AT94924764 T AT 94924764T AT E215949 T1 ATE215949 T1 AT E215949T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- derivatives
- sec
- nitrogen
- zero
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical class C* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- LRGZZEOWQURWFK-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7-octahydroisoquinoline Chemical class C1NCCC2CCCC=C21 LRGZZEOWQURWFK-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229940125692 cardiovascular agent Drugs 0.000 abstract 1
- 239000002327 cardiovascular agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Lubricants (AREA)
- Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT93MI001788A IT1265043B1 (it) | 1993-08-06 | 1993-08-06 | Derivati di idroisochinolina |
| ITMI940202A IT1274008B (it) | 1994-02-04 | 1994-02-04 | Derivati di idroisochinolina |
| PCT/EP1994/002325 WO1995004734A1 (en) | 1993-08-06 | 1994-07-14 | Hydroisoquinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE215949T1 true ATE215949T1 (de) | 2002-04-15 |
Family
ID=26331034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94924764T ATE215949T1 (de) | 1993-08-06 | 1994-07-14 | Hydroisochinolinderivate |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5731322A (de) |
| EP (1) | EP0712402B1 (de) |
| JP (1) | JPH09505030A (de) |
| CN (1) | CN1043641C (de) |
| AT (1) | ATE215949T1 (de) |
| AU (1) | AU690576B2 (de) |
| CA (1) | CA2168853A1 (de) |
| DE (1) | DE69430373T2 (de) |
| ES (1) | ES2173921T3 (de) |
| NZ (1) | NZ271338A (de) |
| WO (1) | WO1995004734A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002322720B2 (en) | 2001-07-25 | 2008-11-13 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| ES2278065T3 (es) | 2001-10-15 | 2007-08-01 | Janssen Pharmaceutica N.V. | Nuevos derivados de 4-fenil-4-(1h-imidazol-2-il)-piperidina sustituida y su uso como agonistas selectivos de opioides delta no peptidos. |
| AU2004278414B2 (en) | 2003-10-01 | 2012-05-24 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| US7087749B2 (en) * | 2004-03-11 | 2006-08-08 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| US7598261B2 (en) | 2005-03-31 | 2009-10-06 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| CN102379684B (zh) | 2005-04-28 | 2014-11-19 | 普罗透斯数字保健公司 | 药物信息系统 |
| US7576207B2 (en) | 2006-04-06 | 2009-08-18 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| EP2399577A1 (de) | 2006-09-12 | 2011-12-28 | Adolor Corporation | Verwendung von N-haltigen Spiroverbindungen zur Verbesserung der kognitiven Funktion |
| KR20090071598A (ko) | 2006-09-18 | 2009-07-01 | 랩터 파마슈티컬 인코포레이티드 | 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료 |
| US7645801B2 (en) * | 2007-01-29 | 2010-01-12 | Alaven Pharmaceutical Llc | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
| EP2398500B1 (de) | 2009-02-20 | 2019-03-13 | 2-BBB Medicines B.V. | Arzneiabgabesystem auf glutathion-basis |
| ES2942923T3 (es) | 2009-05-06 | 2023-06-07 | Laboratory Skin Care Inc | Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas |
| US20100311782A1 (en) * | 2009-06-08 | 2010-12-09 | Adolor Corporation | Substituted piperidinylpropanoic acid compounds and methods of their use |
| US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
| CN103298343A (zh) | 2011-01-07 | 2013-09-11 | 科赛普特治疗公司 | 类固醇和糖皮质激素受体拮抗剂组合疗法 |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| EP4219494B1 (de) | 2013-11-25 | 2026-03-25 | Corcept Therapeutics Incorporated | Octahydrokondensierte azadekalin-glucocorticoid-rezeptor-modulatoren |
| SG11201908790PA (en) | 2017-03-31 | 2019-10-30 | Corcept Therapeutics Inc | Glucocorticoid receptor modulators to treat cervical cancer |
| AU2019404026B2 (en) | 2018-12-19 | 2023-06-08 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CA3131263C (en) | 2019-02-22 | 2024-01-02 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| CN113105411B (zh) * | 2019-06-28 | 2023-03-17 | 深圳市三启药物开发有限公司 | 腙酰胺类衍生物及药物组合物 |
| US11903945B2 (en) | 2019-12-11 | 2024-02-20 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| KR20230017829A (ko) | 2020-05-27 | 2023-02-06 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 글루코코르티코이드 수용체 조절제 렐라코릴란트 및 cyp2c8과 cyp3a4의 이중 기질인 파클리탁셀의 병용 투여 |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12616698B2 (en) | 2021-05-05 | 2026-05-05 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| WO2024077169A1 (en) | 2022-10-06 | 2024-04-11 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| US12433882B2 (en) | 2022-10-28 | 2025-10-07 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260762A (en) * | 1979-09-10 | 1981-04-07 | Hoffmann-La Roche Inc. | Octahydro-1H-pyrrolo[2,3-g]isoquinolines |
| ES2173866T3 (es) * | 1991-07-05 | 2002-11-01 | Glaxosmithkline Spa | Derivados de hidroisoquinolina. |
-
1994
- 1994-07-14 DE DE69430373T patent/DE69430373T2/de not_active Expired - Fee Related
- 1994-07-14 NZ NZ271338A patent/NZ271338A/en unknown
- 1994-07-14 JP JP7506175A patent/JPH09505030A/ja not_active Ceased
- 1994-07-14 CN CN94193633A patent/CN1043641C/zh not_active Expired - Fee Related
- 1994-07-14 US US08/591,514 patent/US5731322A/en not_active Expired - Fee Related
- 1994-07-14 AU AU74937/94A patent/AU690576B2/en not_active Ceased
- 1994-07-14 CA CA002168853A patent/CA2168853A1/en not_active Abandoned
- 1994-07-14 WO PCT/EP1994/002325 patent/WO1995004734A1/en not_active Ceased
- 1994-07-14 ES ES94924764T patent/ES2173921T3/es not_active Expired - Lifetime
- 1994-07-14 AT AT94924764T patent/ATE215949T1/de not_active IP Right Cessation
- 1994-07-14 EP EP94924764A patent/EP0712402B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69430373T2 (de) | 2002-12-12 |
| DE69430373D1 (de) | 2002-05-16 |
| WO1995004734A1 (en) | 1995-02-16 |
| NZ271338A (en) | 1998-06-26 |
| CA2168853A1 (en) | 1995-02-16 |
| AU690576B2 (en) | 1998-04-30 |
| ES2173921T3 (es) | 2002-11-01 |
| CN1132510A (zh) | 1996-10-02 |
| EP0712402B1 (de) | 2002-04-10 |
| US5731322A (en) | 1998-03-24 |
| AU7493794A (en) | 1995-02-28 |
| CN1043641C (zh) | 1999-06-16 |
| EP0712402A1 (de) | 1996-05-22 |
| JPH09505030A (ja) | 1997-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69430373D1 (de) | Hydroisochinolinderivate | |
| TW367327B (en) | Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation and their use | |
| DE69618231D1 (de) | TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER | |
| IL123701A0 (en) | Heterocyclic fungicides | |
| NZ331001A (en) | Use of an opiate K receptor agonist as an antipruritic | |
| MY102842A (en) | Calcium independent camp phosphodiesterase inhibitor antidepressant | |
| NO20003133D0 (no) | Anilidderivater, fremstilling og anvendelse derav | |
| AU2003301020A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| YU231790A (sh) | Spirocikli koji sadrže azot | |
| GR3036657T3 (en) | Method of preventing nmda receptor-mediated neuronal damage. | |
| IL141410A0 (en) | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) | |
| KR950701911A (ko) | 피페리딘 유도체를 유효성분으로 하는 말초혈관확장제(peripheral vaso-dilating agent containing piperidine derivative as active ingredient) | |
| NZ233735A (en) | Heterocyclic substituted aminophenol derivatives | |
| ATE302606T1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
| MY108885A (en) | Heterocyclic-cyclic amine derivatives. | |
| ATE175661T1 (de) | Benzamid-derivate als vasopressin-antagonisten | |
| MY117092A (en) | Chemotherapeutic pyrrolocarbazole derivatives | |
| DE69733843D1 (de) | Zusammensetzungen und verwendungvon benzamiden als entzuendungshemmende mittel | |
| DK0960111T3 (da) | Morphinderivat med analgesisk aktivitet | |
| DE59510713D1 (de) | N-substituierte 3-azabicyclo(3.2.0)heptan-derivate als neuroleptika | |
| DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
| DE3671890D1 (de) | Benzylaminoxidaseinhibitoren, selektiv in beziehung auf andere aminoxidasen. | |
| MX9709466A (es) | Medicamento para inhibir el melanoma. | |
| ATE47135T1 (de) | Antikonvulsive mittel. | |
| DE69526097D1 (de) | Bicyclische carboxamide als 5-ht1a rezeptoren liganden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |